US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi (NASDAQ: SNY) from its subsidiary Libertas Bio. The agreement includes an upfront payment and potential milestone payments totaling up to EUR 545 million (USD 642 million), plus tiered royalties on future sales.
Sanofi’s Development Plans
Sanofi will conduct a Phase I study to explore gusacitinib’s potential in novel, previously unstudied indications. This marks the transition of gusacitinib to next-phase development under Sanofi’s global commercialization expertise.
Background of Gusacitinib Acquisition
Formation Bio, formerly known as TrialSpark, acquired gusacitinib from Asana BioSciences as part of a broader portfolio deal. This transaction represents a significant step forward in the drug’s development journey.-Fineline Info & Tech
